Literature DB >> 22509477

Human ABCG2: structure, function, and its role in multidrug resistance.

Wei Mo1, Jian-Ting Zhang.   

Abstract

Human ABCG2 is a member of the ATP-binding cassette (ABC) transporter superfamily and is known to contribute to multidrug resistance (MDR) in cancer chemotherapy. Among ABC transporters that are known to cause MDR, ABCG2 is particularly interesting for its potential role in protecting cancer stem cells and its complex oligomeric structure. Recent studies have also revealed that the biogenesis of ABCG2 could be modulated by small molecule compounds. These modulators, upon binding to ABCG2, accelerate the endocytosis and trafficking to lysosome for degradation and effectively reduce the half-life of ABCG2. Hence, targeting ABCG2 stability could be a new venue for therapeutic discovery to sensitize drug resistant human cancers. In this report, we review recent progress on understanding the structure, function, biogenesis, as well as physiological and pathophysiological functions of ABCG2.

Entities:  

Keywords:  ATP-binding cassette; Human ABCG2; cancer; chemotherapy; function; multidrug resistance; structure

Year:  2011        PMID: 22509477      PMCID: PMC3325772     

Source DB:  PubMed          Journal:  Int J Biochem Mol Biol        ISSN: 2152-4114


  254 in total

1.  Xanthines down-regulate the drug transporter ABCG2 and reverse multidrug resistance.

Authors:  Rui Ding; Jia Shi; Kirk Pabon; Kathleen W Scotto
Journal:  Mol Pharmacol       Date:  2011-11-23       Impact factor: 4.436

2.  Estradiol induces export of sphingosine 1-phosphate from breast cancer cells via ABCC1 and ABCG2.

Authors:  Kazuaki Takabe; Roger H Kim; Jeremy C Allegood; Poulami Mitra; Subramaniam Ramachandran; Masayuki Nagahashi; Kuzhuvelil B Harikumar; Nitai C Hait; Sheldon Milstien; Sarah Spiegel
Journal:  J Biol Chem       Date:  2010-01-28       Impact factor: 5.157

3.  Cyclosporin A is a broad-spectrum multidrug resistance modulator.

Authors:  Misbah Qadir; Kieran L O'Loughlin; Stacy M Fricke; Nicole A Williamson; William R Greco; Hans Minderman; Maria R Baer
Journal:  Clin Cancer Res       Date:  2005-03-15       Impact factor: 12.531

4.  Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux.

Authors:  E L Volk; K Rohde; M Rhee; J J McGuire; L A Doyle; D D Ross; E Schneider
Journal:  Cancer Res       Date:  2000-07-01       Impact factor: 12.701

5.  Flow cytometry-based approach to ABCG2 function suggests that the transporter differentially handles the influx and efflux of drugs.

Authors:  Marta García-Escarp; Vanessa Martínez-Muñoz; Irene Sales-Pardo; Jordi Barquinero; Joan Carles Domingo; Pedro Marin; Jordi Petriz
Journal:  Cytometry A       Date:  2004-12       Impact factor: 4.355

6.  RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response.

Authors:  Herman Burger; John A Foekens; Maxime P Look; Marion E Meijer-van Gelder; Jan G M Klijn; Erik A C Wiemer; Gerrit Stoter; Kees Nooter
Journal:  Clin Cancer Res       Date:  2003-02       Impact factor: 12.531

7.  Dynamic vs static ABCG2 inhibitors to sensitize drug resistant cancer cells.

Authors:  Hui Peng; Jing Qi; Zizheng Dong; Jian-Ting Zhang
Journal:  PLoS One       Date:  2010-12-07       Impact factor: 3.240

8.  In vitro and in vivo interaction of moxidectin with BCRP/ABCG2.

Authors:  Miriam Perez; Alba G Blazquez; Rebeca Real; Gracia Mendoza; Julio G Prieto; Gracia Merino; Ana I Alvarez
Journal:  Chem Biol Interact       Date:  2009-02-23       Impact factor: 5.192

9.  Breast cancer resistance protein exports sulfated estrogens but not free estrogens.

Authors:  Yasuo Imai; Sakiyo Asada; Satomi Tsukahara; Etsuko Ishikawa; Takashi Tsuruo; Yoshikazu Sugimoto
Journal:  Mol Pharmacol       Date:  2003-09       Impact factor: 4.436

10.  In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2.

Authors:  Serena Marchetti; Roos L Oostendorp; Dick Pluim; Monique van Eijndhoven; Olaf van Tellingen; Alfred H Schinkel; Richard Versace; Jos H Beijnen; Roberto Mazzanti; Jan H Schellens
Journal:  Mol Cancer Ther       Date:  2007-12       Impact factor: 6.261

View more
  75 in total

1.  A high-content assay strategy for the identification and profiling of ABCG2 modulators in live cells.

Authors:  Christophe Antczak; Boyoung Wee; Constantin Radu; Bhavneet Bhinder; Eric C Holland; Hakim Djaballah
Journal:  Assay Drug Dev Technol       Date:  2013-08-30       Impact factor: 1.738

2.  Transcription factors Sp1 and Sp3 regulate expression of human ABCG2 gene and chemoresistance phenotype.

Authors:  Wook-Jin Yang; Min-Ji Song; Eun Young Park; Jong-Joo Lee; Joo-Hong Park; Keunhee Park; Jong Hoon Park; Hyoung-Pyo Kim
Journal:  Mol Cells       Date:  2013-08-29       Impact factor: 5.034

3.  SP/drug efflux functionality of hematopoietic progenitors is controlled by mesenchymal niche through VLA-4/CD44 axis.

Authors:  J-V Malfuson; L Boutin; D Clay; C Thépenier; C Desterke; F Torossian; B Guerton; A Anginot; T de Revel; J-J Lataillade; M-C Le Bousse-Kerdilès
Journal:  Leukemia       Date:  2013-09-03       Impact factor: 11.528

4.  Role of ABCG2 expression driven by cisplatin in platinum-containing chemotherapy for gastric cancer.

Authors:  Qiang Zhang; Kun Li; Jian-Hua Xu; Cheng-Gen Zhao; Qi Gao; Bin Wu; Xiao-Yan Liu
Journal:  World J Gastroenterol       Date:  2013-10-21       Impact factor: 5.742

5.  Prognostic impact of membranous ATP-binding cassette Sub-family G member 2 expression in patients with colorectal carcinoma after surgical resection.

Authors:  Donghoon Kang; Jae Myung Park; Chan Kwon Jung; Bo-In Lee; Seong Taek Oh; Myung-Gyu Choi
Journal:  Cancer Biol Ther       Date:  2015-07-15       Impact factor: 4.742

6.  Structure of the human multidrug transporter ABCG2.

Authors:  Nicholas M I Taylor; Ioannis Manolaridis; Scott M Jackson; Julia Kowal; Henning Stahlberg; Kaspar P Locher
Journal:  Nature       Date:  2017-05-29       Impact factor: 49.962

Review 7.  ABCG2 inhibition as a therapeutic approach for overcoming multidrug resistance in cancer.

Authors:  Maryam Hosseini Hasanabady; Fatemeh Kalalinia
Journal:  J Biosci       Date:  2016-06       Impact factor: 1.826

8.  SOX11 identified by target gene evaluation of miRNAs differentially expressed in focal and non-focal brain tissue of therapy-resistant epilepsy patients.

Authors:  Sierk Haenisch; Yi Zhao; Aparna Chhibber; Kitti Kaiboriboon; Lynn V Do; Silke Vogelgesang; Nicholas M Barbaro; Brian K Alldredge; Daniel H Lowenstein; Ingolf Cascorbi; Deanna L Kroetz
Journal:  Neurobiol Dis       Date:  2015-03-10       Impact factor: 5.996

9.  ABCG2 expression in colorectal adenocarcinomas may predict resistance to irinotecan.

Authors:  Hoang Dinh Tuy; Hisanori Shiomi; Ken Ichi Mukaisho; Shigeyuki Naka; Tomoharu Shimizu; Hiromichi Sonoda; Eiji Mekata; Yoshihiro Endo; Yoshimasa Kurumi; Hiroyuki Sugihara; Masaji Tani; Tohru Tani
Journal:  Oncol Lett       Date:  2016-08-03       Impact factor: 2.967

Review 10.  PharmGKB summary: very important pharmacogene information for ABCG2.

Authors:  Alison E Fohner; Deanna J Brackman; Kathleen M Giacomini; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2017-11       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.